Dr reddy's laboratories ltd RDY.US Overview Analysis
RDY AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has received the highest rating for its value, and its dividend score is solid. It's ideal for long-term position building. For optimal entry, check our trend or swing trading rating.
RDY Current Performance
-0.16%
Dr reddy's laboratories ltd
2.24%
Avg of Sector
0.40%
S&P500
Top 10 High Relevance to RDY
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
VTRS | Viatris inc | 4 | 5 | 2 | 4 | 4 | |
NVS | Novartis ag | 3 | 5 | 3 | 3 | 5 | |
MGNX | Macrogenics inc | 3 | 3 | 2 | 1 | 1 | |
KPTI | Karyopharm therapeutics inc | 4 | 3 | 2 | 1 | 1 | |
AZN | Astrazeneca plc | 3 | 1 | 2 | 2 | 5 |
- VTRS Viatris incValue 4Trend 5Swing Trading 2Whale Interest 4Dividend 4See more
RDY Profile
Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.